Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) Stock Competitors & Peer Comparison
See PRISMMEDI.BO's competitors and their performance on the BSE and across the wider stock market.
Peer Comparison Table: Financial - Conglomerates Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PRISMMEDI.BO and its BSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PRISMMEDI.BO | ₹29.65 | +1.72% | 179.8M | 94.76 | ₹0.31 | N/A |
| BAJAJFINSV.BO | ₹2,028.65 | +0.60% | 3.3T | 31.94 | ₹63.51 | +0.07% |
| BAJAJFINSV.NS | ₹2,032.50 | +0.82% | 3.2T | 31.97 | ₹63.57 | +0.07% |
| ABCAPITAL.NS | ₹413.00 | +0.98% | 1.1T | 32.88 | ₹12.56 | N/A |
| ABCAPITAL.BO | ₹412.00 | +0.98% | 1.1T | 32.65 | ₹12.62 | N/A |
| AIIL.BO | ₹553.80 | +4.15% | 469.6B | 24.23 | ₹22.81 | N/A |
| AIIL.NS | ₹552.25 | +3.75% | 469B | 24.21 | ₹22.81 | N/A |
| PEL.BO | ₹1,124.60 | +0.25% | 254.9B | 44.24 | ₹25.42 | N/A |
| INDIGRID-IV.NS | ₹176.08 | +0.00% | 167.7B | 38.53 | ₹4.57 | +9.15% |
| INDIGRID.NS | ₹176.08 | +0.32% | 167.7B | 39.22 | ₹4.49 | +9.15% |
Stock Comparison
Bajaj Finserv Ltd. (BSE: BAJAJFINSV.BO)
PRISMMEDI.BO vs BAJAJFINSV.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, BAJAJFINSV.BO has a market cap of 3.3T. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while BAJAJFINSV.BO trades at ₹2,028.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas BAJAJFINSV.BO's P/E ratio is 31.94. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to BAJAJFINSV.BO's ROE of +0.09%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to BAJAJFINSV.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check BAJAJFINSV.BO's competition here
Bajaj Finserv Ltd. (NSE: BAJAJFINSV.NS)
PRISMMEDI.BO vs BAJAJFINSV.NS Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, BAJAJFINSV.NS has a market cap of 3.2T. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while BAJAJFINSV.NS trades at ₹2,032.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas BAJAJFINSV.NS's P/E ratio is 31.97. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to BAJAJFINSV.NS's ROE of +0.09%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to BAJAJFINSV.NS. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check BAJAJFINSV.NS's competition here
Aditya Birla Capital Limited (NSE: ABCAPITAL.NS)
PRISMMEDI.BO vs ABCAPITAL.NS Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, ABCAPITAL.NS has a market cap of 1.1T. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while ABCAPITAL.NS trades at ₹413.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas ABCAPITAL.NS's P/E ratio is 32.88. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to ABCAPITAL.NS's ROE of +0.12%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to ABCAPITAL.NS. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check ABCAPITAL.NS's competition here
Aditya Birla Capital Limited (BSE: ABCAPITAL.BO)
PRISMMEDI.BO vs ABCAPITAL.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, ABCAPITAL.BO has a market cap of 1.1T. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while ABCAPITAL.BO trades at ₹412.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas ABCAPITAL.BO's P/E ratio is 32.65. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to ABCAPITAL.BO's ROE of +0.12%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to ABCAPITAL.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check ABCAPITAL.BO's competition here
Authum Investment & Infrastructure Limited (BSE: AIIL.BO)
PRISMMEDI.BO vs AIIL.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, AIIL.BO has a market cap of 469.6B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while AIIL.BO trades at ₹553.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas AIIL.BO's P/E ratio is 24.23. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to AIIL.BO's ROE of +0.14%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to AIIL.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check AIIL.BO's competition here
Authum Investment & Infrastructure Limited (NSE: AIIL.NS)
PRISMMEDI.BO vs AIIL.NS Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, AIIL.NS has a market cap of 469B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while AIIL.NS trades at ₹552.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas AIIL.NS's P/E ratio is 24.21. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to AIIL.NS's ROE of +0.14%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to AIIL.NS. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check AIIL.NS's competition here
Piramal Enterprises Limited (BSE: PEL.BO)
PRISMMEDI.BO vs PEL.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, PEL.BO has a market cap of 254.9B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while PEL.BO trades at ₹1,124.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas PEL.BO's P/E ratio is 44.24. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to PEL.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to PEL.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check PEL.BO's competition here
IndiGrid Infrastructure Trust (NSE: INDIGRID-IV.NS)
PRISMMEDI.BO vs INDIGRID-IV.NS Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, INDIGRID-IV.NS has a market cap of 167.7B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while INDIGRID-IV.NS trades at ₹176.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas INDIGRID-IV.NS's P/E ratio is 38.53. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to INDIGRID-IV.NS's ROE of +0.10%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to INDIGRID-IV.NS. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check INDIGRID-IV.NS's competition here
IndiGrid Infrastructure Trust (NSE: INDIGRID.NS)
PRISMMEDI.BO vs INDIGRID.NS Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, INDIGRID.NS has a market cap of 167.7B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while INDIGRID.NS trades at ₹176.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas INDIGRID.NS's P/E ratio is 39.22. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to INDIGRID.NS's ROE of +0.10%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to INDIGRID.NS. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check INDIGRID.NS's competition here
Edelweiss Financial Services Limited (NSE: EDELWEISS.NS)
PRISMMEDI.BO vs EDELWEISS.NS Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, EDELWEISS.NS has a market cap of 121.8B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while EDELWEISS.NS trades at ₹128.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas EDELWEISS.NS's P/E ratio is 17.23. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to EDELWEISS.NS's ROE of +0.12%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to EDELWEISS.NS. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check EDELWEISS.NS's competition here
Edelweiss Financial Services Limited (BSE: EDELWEISS.BO)
PRISMMEDI.BO vs EDELWEISS.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, EDELWEISS.BO has a market cap of 121.8B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while EDELWEISS.BO trades at ₹128.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas EDELWEISS.BO's P/E ratio is 17.82. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to EDELWEISS.BO's ROE of +0.12%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to EDELWEISS.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check EDELWEISS.BO's competition here
Elcid Investments Ltd. (BSE: ELCIDIN.BO)
PRISMMEDI.BO vs ELCIDIN.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, ELCIDIN.BO has a market cap of 21.8B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while ELCIDIN.BO trades at ₹109,200.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas ELCIDIN.BO's P/E ratio is 20.13. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to ELCIDIN.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to ELCIDIN.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check ELCIDIN.BO's competition here
Saraswati Commercial (India) Limited (BSE: ZSARACOM.BO)
PRISMMEDI.BO vs ZSARACOM.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, ZSARACOM.BO has a market cap of 13.7B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while ZSARACOM.BO trades at ₹12,500.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas ZSARACOM.BO's P/E ratio is -60.12. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to ZSARACOM.BO's ROE of +0.13%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to ZSARACOM.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check ZSARACOM.BO's competition here
Crest Ventures Limited (NSE: CREST.NS)
PRISMMEDI.BO vs CREST.NS Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, CREST.NS has a market cap of 10.3B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while CREST.NS trades at ₹361.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas CREST.NS's P/E ratio is 29.91. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to CREST.NS's ROE of +0.03%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to CREST.NS. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check CREST.NS's competition here
Crest Ventures Limited (BSE: CREST.BO)
PRISMMEDI.BO vs CREST.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, CREST.BO has a market cap of 10.1B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while CREST.BO trades at ₹357.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas CREST.BO's P/E ratio is 29.58. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to CREST.BO's ROE of +0.03%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to CREST.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check CREST.BO's competition here
Consolidated Finvest & Holdings Limited (NSE: CONSOFINVT.NS)
PRISMMEDI.BO vs CONSOFINVT.NS Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, CONSOFINVT.NS has a market cap of 8.8B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while CONSOFINVT.NS trades at ₹272.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas CONSOFINVT.NS's P/E ratio is 13.62. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to CONSOFINVT.NS's ROE of +0.05%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to CONSOFINVT.NS. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check CONSOFINVT.NS's competition here
Fedders Holding Ltd (BSE: FEDDERSHOL.BO)
PRISMMEDI.BO vs FEDDERSHOL.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, FEDDERSHOL.BO has a market cap of 8.1B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while FEDDERSHOL.BO trades at ₹40.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas FEDDERSHOL.BO's P/E ratio is 0.95. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to FEDDERSHOL.BO's ROE of +0.12%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to FEDDERSHOL.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check FEDDERSHOL.BO's competition here
Reliance Capital Limited (NSE: RELCAPITAL.NS)
PRISMMEDI.BO vs RELCAPITAL.NS Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, RELCAPITAL.NS has a market cap of 3.1B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while RELCAPITAL.NS trades at ₹12.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas RELCAPITAL.NS's P/E ratio is 0.46. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to RELCAPITAL.NS's ROE of -0.02%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to RELCAPITAL.NS. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check RELCAPITAL.NS's competition here
Kartik Investments Trust Limited (BSE: KARTKIN.BO)
PRISMMEDI.BO vs KARTKIN.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, KARTKIN.BO has a market cap of 2.4B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while KARTKIN.BO trades at ₹9,986.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas KARTKIN.BO's P/E ratio is 47.71. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to KARTKIN.BO's ROE of N/A. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to KARTKIN.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check KARTKIN.BO's competition here
Gourmet Gateway India Ltd (BSE: GOURMET.BO)
PRISMMEDI.BO vs GOURMET.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, GOURMET.BO has a market cap of 1.9B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while GOURMET.BO trades at ₹12.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas GOURMET.BO's P/E ratio is 158.42. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to GOURMET.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to GOURMET.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check GOURMET.BO's competition here
Lexora Global Limited (BSE: YASTF.BO)
PRISMMEDI.BO vs YASTF.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, YASTF.BO has a market cap of 1.8B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while YASTF.BO trades at ₹176.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas YASTF.BO's P/E ratio is 60.58. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to YASTF.BO's ROE of +0.12%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to YASTF.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check YASTF.BO's competition here
Intellivate Capital Ventures Limited (BSE: INTELLCAP.BO)
PRISMMEDI.BO vs INTELLCAP.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, INTELLCAP.BO has a market cap of 1.3B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while INTELLCAP.BO trades at ₹45.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas INTELLCAP.BO's P/E ratio is 1097.56. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to INTELLCAP.BO's ROE of +0.12%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to INTELLCAP.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check INTELLCAP.BO's competition here
RSD Finance Limited (BSE: RSDFIN.BO)
PRISMMEDI.BO vs RSDFIN.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, RSDFIN.BO has a market cap of 1.3B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while RSDFIN.BO trades at ₹101.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas RSDFIN.BO's P/E ratio is 32.37. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to RSDFIN.BO's ROE of +0.06%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to RSDFIN.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check RSDFIN.BO's competition here
Arunjyoti Bio Ventures Limited (BSE: ABVL.BO)
PRISMMEDI.BO vs ABVL.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, ABVL.BO has a market cap of 939.4M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while ABVL.BO trades at ₹5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas ABVL.BO's P/E ratio is -56.00. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to ABVL.BO's ROE of -0.19%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to ABVL.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check ABVL.BO's competition here
Milgrey Finance and Investments Limited (BSE: ZMILGFIN.BO)
PRISMMEDI.BO vs ZMILGFIN.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, ZMILGFIN.BO has a market cap of 918.7M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while ZMILGFIN.BO trades at ₹42.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas ZMILGFIN.BO's P/E ratio is -2098.92. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to ZMILGFIN.BO's ROE of -0.06%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to ZMILGFIN.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check ZMILGFIN.BO's competition here
NCL Research & Financial Services Limited (BSE: NCLRESE.BO)
PRISMMEDI.BO vs NCLRESE.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, NCLRESE.BO has a market cap of 824.2M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while NCLRESE.BO trades at ₹0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas NCLRESE.BO's P/E ratio is 78.25. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to NCLRESE.BO's ROE of -0.03%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to NCLRESE.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check NCLRESE.BO's competition here
Fervent Synergies Limited (BSE: FERVENTSYN.BO)
PRISMMEDI.BO vs FERVENTSYN.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, FERVENTSYN.BO has a market cap of 800.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while FERVENTSYN.BO trades at ₹16.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas FERVENTSYN.BO's P/E ratio is 21.07. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to FERVENTSYN.BO's ROE of +0.07%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to FERVENTSYN.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check FERVENTSYN.BO's competition here
Yamini Investments Company Limited (BSE: YAMNINV.BO)
PRISMMEDI.BO vs YAMNINV.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, YAMNINV.BO has a market cap of 598M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while YAMNINV.BO trades at ₹0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas YAMNINV.BO's P/E ratio is 22.00. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to YAMNINV.BO's ROE of +0.00%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to YAMNINV.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check YAMNINV.BO's competition here
Apoorva Leasing Finance and Investment Company Limited (BSE: APOORVA.BO)
PRISMMEDI.BO vs APOORVA.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, APOORVA.BO has a market cap of 551.9M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while APOORVA.BO trades at ₹27.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas APOORVA.BO's P/E ratio is 172.69. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to APOORVA.BO's ROE of +0.00%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to APOORVA.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check APOORVA.BO's competition here
Regis Industries Ltd. (BSE: REGIS.BO)
PRISMMEDI.BO vs REGIS.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, REGIS.BO has a market cap of 542M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while REGIS.BO trades at ₹2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas REGIS.BO's P/E ratio is -9.62. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to REGIS.BO's ROE of +0.04%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to REGIS.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check REGIS.BO's competition here
India Cements Capital Limited (BSE: INDCEMCAP.BO)
PRISMMEDI.BO vs INDCEMCAP.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, INDCEMCAP.BO has a market cap of 514.2M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while INDCEMCAP.BO trades at ₹23.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas INDCEMCAP.BO's P/E ratio is 215.36. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to INDCEMCAP.BO's ROE of -0.03%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to INDCEMCAP.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check INDCEMCAP.BO's competition here
Morgan Ventures Limited (BSE: MORGAN.BO)
PRISMMEDI.BO vs MORGAN.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, MORGAN.BO has a market cap of 435.6M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while MORGAN.BO trades at ₹44.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas MORGAN.BO's P/E ratio is 23.66. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to MORGAN.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to MORGAN.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MORGAN.BO's competition here
Lakshmi Finance & Industrial Corporation Limited (NSE: LFIC.NS)
PRISMMEDI.BO vs LFIC.NS Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, LFIC.NS has a market cap of 422.8M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while LFIC.NS trades at ₹140.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas LFIC.NS's P/E ratio is -7.97. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to LFIC.NS's ROE of +0.02%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to LFIC.NS. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check LFIC.NS's competition here
Lerthai Finance Ltd. (BSE: LERTHAI.BO)
PRISMMEDI.BO vs LERTHAI.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, LERTHAI.BO has a market cap of 399.9M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while LERTHAI.BO trades at ₹571.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas LERTHAI.BO's P/E ratio is -136.58. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to LERTHAI.BO's ROE of -0.06%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to LERTHAI.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check LERTHAI.BO's competition here
Toyam Sports Ltd. (BSE: TOYAMSL.BO)
PRISMMEDI.BO vs TOYAMSL.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, TOYAMSL.BO has a market cap of 381.4M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while TOYAMSL.BO trades at ₹0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas TOYAMSL.BO's P/E ratio is 71.27. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to TOYAMSL.BO's ROE of -0.05%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to TOYAMSL.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check TOYAMSL.BO's competition here
K K Fincorp Limited (BSE: KKFIN.BO)
PRISMMEDI.BO vs KKFIN.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, KKFIN.BO has a market cap of 329.2M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while KKFIN.BO trades at ₹58.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas KKFIN.BO's P/E ratio is N/A. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to KKFIN.BO's ROE of +0.00%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to KKFIN.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check KKFIN.BO's competition here
Harmony Capital Services Limited (BSE: HRMNYCP.BO)
PRISMMEDI.BO vs HRMNYCP.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, HRMNYCP.BO has a market cap of 308.2M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while HRMNYCP.BO trades at ₹102.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas HRMNYCP.BO's P/E ratio is 115.43. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to HRMNYCP.BO's ROE of +1.95%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to HRMNYCP.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check HRMNYCP.BO's competition here
Margo Finance Limited (BSE: MARGOFIN.BO)
PRISMMEDI.BO vs MARGOFIN.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, MARGOFIN.BO has a market cap of 299.8M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while MARGOFIN.BO trades at ₹65.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas MARGOFIN.BO's P/E ratio is 27.92. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to MARGOFIN.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to MARGOFIN.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MARGOFIN.BO's competition here
Medico Intercontinental Limite (BSE: MIL.BO)
PRISMMEDI.BO vs MIL.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, MIL.BO has a market cap of 291.7M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while MIL.BO trades at ₹29.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas MIL.BO's P/E ratio is -9.12. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to MIL.BO's ROE of -0.10%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to MIL.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MIL.BO's competition here
Invigorated Business Consultin (BSE: INVIGO.BO)
PRISMMEDI.BO vs INVIGO.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, INVIGO.BO has a market cap of 287.4M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while INVIGO.BO trades at ₹7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas INVIGO.BO's P/E ratio is 6375.00. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to INVIGO.BO's ROE of +0.00%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to INVIGO.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check INVIGO.BO's competition here
Qgo Finance Ltd. (BSE: QGO.BO)
PRISMMEDI.BO vs QGO.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, QGO.BO has a market cap of 285.3M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while QGO.BO trades at ₹41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas QGO.BO's P/E ratio is 11.66. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to QGO.BO's ROE of +0.18%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to QGO.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check QGO.BO's competition here
Morarka Finance Limited (BSE: MORARKFI.BO)
PRISMMEDI.BO vs MORARKFI.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, MORARKFI.BO has a market cap of 284.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while MORARKFI.BO trades at ₹63.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas MORARKFI.BO's P/E ratio is 50.97. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to MORARKFI.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to MORARKFI.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MORARKFI.BO's competition here
Williamson Magor & Co. Ltd. (NSE: WILLAMAGOR.NS)
PRISMMEDI.BO vs WILLAMAGOR.NS Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, WILLAMAGOR.NS has a market cap of 274.3M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while WILLAMAGOR.NS trades at ₹25.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas WILLAMAGOR.NS's P/E ratio is -1.47. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to WILLAMAGOR.NS's ROE of +0.08%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to WILLAMAGOR.NS. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check WILLAMAGOR.NS's competition here
Swarna Securities Limited (BSE: SWRNASE.BO)
PRISMMEDI.BO vs SWRNASE.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, SWRNASE.BO has a market cap of 267M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while SWRNASE.BO trades at ₹89.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas SWRNASE.BO's P/E ratio is 43.20. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to SWRNASE.BO's ROE of +0.10%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to SWRNASE.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check SWRNASE.BO's competition here
Johnson Pharmacare Ltd. (BSE: JOHNPHARMA.BO)
PRISMMEDI.BO vs JOHNPHARMA.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, JOHNPHARMA.BO has a market cap of 258.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while JOHNPHARMA.BO trades at ₹0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas JOHNPHARMA.BO's P/E ratio is -5875.00. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to JOHNPHARMA.BO's ROE of -1.51%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to JOHNPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check JOHNPHARMA.BO's competition here
Sterling Guaranty & Finance Limited (BSE: STRLGUA.BO)
PRISMMEDI.BO vs STRLGUA.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, STRLGUA.BO has a market cap of 255M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while STRLGUA.BO trades at ₹39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas STRLGUA.BO's P/E ratio is -136.84. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to STRLGUA.BO's ROE of +0.07%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to STRLGUA.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check STRLGUA.BO's competition here
TCFC Finance Limited (BSE: TCFCFINQ.BO)
PRISMMEDI.BO vs TCFCFINQ.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, TCFCFINQ.BO has a market cap of 249.7M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while TCFCFINQ.BO trades at ₹25.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas TCFCFINQ.BO's P/E ratio is 114.09. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to TCFCFINQ.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to TCFCFINQ.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check TCFCFINQ.BO's competition here
Williamson Magor & Co. Limited (BSE: WILLAMAGOR.BO)
PRISMMEDI.BO vs WILLAMAGOR.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, WILLAMAGOR.BO has a market cap of 247.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while WILLAMAGOR.BO trades at ₹23.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas WILLAMAGOR.BO's P/E ratio is -1.74. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to WILLAMAGOR.BO's ROE of +0.08%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to WILLAMAGOR.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check WILLAMAGOR.BO's competition here
Oasis Securities Limited (BSE: OASISEC.BO)
PRISMMEDI.BO vs OASISEC.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, OASISEC.BO has a market cap of 223.3M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while OASISEC.BO trades at ₹12.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas OASISEC.BO's P/E ratio is 27.45. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to OASISEC.BO's ROE of +0.05%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to OASISEC.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check OASISEC.BO's competition here
Monotype India Limited (BSE: MONOT.BO)
PRISMMEDI.BO vs MONOT.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, MONOT.BO has a market cap of 218M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while MONOT.BO trades at ₹0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas MONOT.BO's P/E ratio is -107.27. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to MONOT.BO's ROE of +0.39%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to MONOT.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MONOT.BO's competition here
Easun Capital Markets Limited (BSE: EASUN.BO)
PRISMMEDI.BO vs EASUN.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, EASUN.BO has a market cap of 208.3M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while EASUN.BO trades at ₹39.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas EASUN.BO's P/E ratio is 56.11. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to EASUN.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to EASUN.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check EASUN.BO's competition here
Global Capital Markets Limited (BSE: GLOBALCA.BO)
PRISMMEDI.BO vs GLOBALCA.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, GLOBALCA.BO has a market cap of 191.2M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while GLOBALCA.BO trades at ₹0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas GLOBALCA.BO's P/E ratio is 1655.17. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to GLOBALCA.BO's ROE of -0.01%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to GLOBALCA.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check GLOBALCA.BO's competition here
Chitradurga Spintex Limited (BSE: CHITRTX.BO)
PRISMMEDI.BO vs CHITRTX.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, CHITRTX.BO has a market cap of 174.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while CHITRTX.BO trades at ₹119.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas CHITRTX.BO's P/E ratio is -52.92. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to CHITRTX.BO's ROE of -0.08%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to CHITRTX.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check CHITRTX.BO's competition here
Shyamkamal Investments Limited (BSE: SHYMINV.BO)
PRISMMEDI.BO vs SHYMINV.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, SHYMINV.BO has a market cap of 168.1M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while SHYMINV.BO trades at ₹12.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas SHYMINV.BO's P/E ratio is 94.23. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to SHYMINV.BO's ROE of +0.02%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to SHYMINV.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check SHYMINV.BO's competition here
Bombay Talkies Ltd (BSE: BOMTALKIES.BO)
PRISMMEDI.BO vs BOMTALKIES.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, BOMTALKIES.BO has a market cap of 162.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while BOMTALKIES.BO trades at ₹3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas BOMTALKIES.BO's P/E ratio is -253.37. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to BOMTALKIES.BO's ROE of -0.04%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to BOMTALKIES.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check BOMTALKIES.BO's competition here
Pressure Sensitive Systems (India) Ltd. (BSE: PRESSURS.BO)
PRISMMEDI.BO vs PRESSURS.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, PRESSURS.BO has a market cap of 157.3M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while PRESSURS.BO trades at ₹1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas PRESSURS.BO's P/E ratio is -6.24. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to PRESSURS.BO's ROE of -0.19%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to PRESSURS.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check PRESSURS.BO's competition here
GSL Securities Ltd (BSE: GSLSEC.BO)
PRISMMEDI.BO vs GSLSEC.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, GSLSEC.BO has a market cap of 149.6M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while GSLSEC.BO trades at ₹35.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas GSLSEC.BO's P/E ratio is -47.95. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to GSLSEC.BO's ROE of -0.05%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to GSLSEC.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check GSLSEC.BO's competition here
Consecutive Investments & Trad (BSE: CITL.BO)
PRISMMEDI.BO vs CITL.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, CITL.BO has a market cap of 147.3M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while CITL.BO trades at ₹0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas CITL.BO's P/E ratio is -1.10. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to CITL.BO's ROE of +0.11%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to CITL.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check CITL.BO's competition here
Kuber Udyog Limited (BSE: KUBERJI.BO)
PRISMMEDI.BO vs KUBERJI.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, KUBERJI.BO has a market cap of 144.1M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while KUBERJI.BO trades at ₹41.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas KUBERJI.BO's P/E ratio is 839.60. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to KUBERJI.BO's ROE of +0.15%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to KUBERJI.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check KUBERJI.BO's competition here
Minolta Finance Limited (BSE: MINOLTAF.BO)
PRISMMEDI.BO vs MINOLTAF.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, MINOLTAF.BO has a market cap of 140.3M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while MINOLTAF.BO trades at ₹1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas MINOLTAF.BO's P/E ratio is 107.76. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to MINOLTAF.BO's ROE of -0.34%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to MINOLTAF.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MINOLTAF.BO's competition here
Decillion Finance Limited (BSE: DFL.BO)
PRISMMEDI.BO vs DFL.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, DFL.BO has a market cap of 136.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while DFL.BO trades at ₹39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas DFL.BO's P/E ratio is 147.56. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to DFL.BO's ROE of -0.01%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to DFL.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check DFL.BO's competition here
Tokyo Finance Limited (BSE: TOKYOFIN.BO)
PRISMMEDI.BO vs TOKYOFIN.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, TOKYOFIN.BO has a market cap of 130.9M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while TOKYOFIN.BO trades at ₹18.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas TOKYOFIN.BO's P/E ratio is 58.69. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to TOKYOFIN.BO's ROE of +0.02%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to TOKYOFIN.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check TOKYOFIN.BO's competition here
Galada Finance Limited (BSE: GALADAFIN.BO)
PRISMMEDI.BO vs GALADAFIN.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, GALADAFIN.BO has a market cap of 117.6M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while GALADAFIN.BO trades at ₹39.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas GALADAFIN.BO's P/E ratio is 31.70. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to GALADAFIN.BO's ROE of +0.08%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to GALADAFIN.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check GALADAFIN.BO's competition here
Garbi Finvest Limited (BSE: GARBIFIN.BO)
PRISMMEDI.BO vs GARBIFIN.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, GARBIFIN.BO has a market cap of 107.2M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while GARBIFIN.BO trades at ₹9.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas GARBIFIN.BO's P/E ratio is -2.94. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to GARBIFIN.BO's ROE of -0.07%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to GARBIFIN.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check GARBIFIN.BO's competition here
Eastcoast Steel Limited (BSE: ECSTSTL.BO)
PRISMMEDI.BO vs ECSTSTL.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, ECSTSTL.BO has a market cap of 106.9M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while ECSTSTL.BO trades at ₹19.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas ECSTSTL.BO's P/E ratio is 18.86. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to ECSTSTL.BO's ROE of +0.04%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to ECSTSTL.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check ECSTSTL.BO's competition here
Ganesh Holdings Ltd (BSE: GANHOLD.BO)
PRISMMEDI.BO vs GANHOLD.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, GANHOLD.BO has a market cap of 86.6M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while GANHOLD.BO trades at ₹97.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas GANHOLD.BO's P/E ratio is 54.03. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to GANHOLD.BO's ROE of +0.04%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to GANHOLD.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check GANHOLD.BO's competition here
Jayabharat Credit Limited (BSE: JAYBHCR.BO)
PRISMMEDI.BO vs JAYBHCR.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, JAYBHCR.BO has a market cap of 69.7M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while JAYBHCR.BO trades at ₹13.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas JAYBHCR.BO's P/E ratio is -6.51. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to JAYBHCR.BO's ROE of +0.02%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to JAYBHCR.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check JAYBHCR.BO's competition here
M Lakhamsi Industries Ltd. (BSE: MLINDLTD.BO)
PRISMMEDI.BO vs MLINDLTD.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, MLINDLTD.BO has a market cap of 66M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while MLINDLTD.BO trades at ₹11.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas MLINDLTD.BO's P/E ratio is 155.15. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to MLINDLTD.BO's ROE of +0.08%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to MLINDLTD.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MLINDLTD.BO's competition here
Agarwal Fortune India Ltd. (BSE: AGARWAL.BO)
PRISMMEDI.BO vs AGARWAL.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, AGARWAL.BO has a market cap of 63.8M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while AGARWAL.BO trades at ₹18.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas AGARWAL.BO's P/E ratio is 103.11. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to AGARWAL.BO's ROE of +0.09%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to AGARWAL.BO. This indicates lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check AGARWAL.BO's competition here
MFS Intercorp Limited (BSE: MFSINTRCRP.BO)
PRISMMEDI.BO vs MFSINTRCRP.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, MFSINTRCRP.BO has a market cap of 60.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while MFSINTRCRP.BO trades at ₹13.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas MFSINTRCRP.BO's P/E ratio is -279.80. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to MFSINTRCRP.BO's ROE of -0.09%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to MFSINTRCRP.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MFSINTRCRP.BO's competition here
Mahan Industries Limited (BSE: MAHANIN.BO)
PRISMMEDI.BO vs MAHANIN.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, MAHANIN.BO has a market cap of 54.9M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while MAHANIN.BO trades at ₹12.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas MAHANIN.BO's P/E ratio is 122.10. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to MAHANIN.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to MAHANIN.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MAHANIN.BO's competition here
Amerise Biosciences Ltd. (BSE: AMERISE.BO)
PRISMMEDI.BO vs AMERISE.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, AMERISE.BO has a market cap of 54.8M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while AMERISE.BO trades at ₹0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas AMERISE.BO's P/E ratio is -90.51. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to AMERISE.BO's ROE of -0.01%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to AMERISE.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check AMERISE.BO's competition here
Beeyu Overseas Ltd. (BSE: BEEYU.BO)
PRISMMEDI.BO vs BEEYU.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, BEEYU.BO has a market cap of 35.4M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while BEEYU.BO trades at ₹2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas BEEYU.BO's P/E ratio is 250.00. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to BEEYU.BO's ROE of -0.11%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to BEEYU.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check BEEYU.BO's competition here
Ventura Guaranty Ltd. (BSE: SHYAM.BO)
PRISMMEDI.BO vs SHYAM.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, SHYAM.BO has a market cap of 0. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while SHYAM.BO trades at ₹8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas SHYAM.BO's P/E ratio is N/A. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to SHYAM.BO's ROE of N/A. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to SHYAM.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check SHYAM.BO's competition here
Shyama Infosys Limited (BSE: SHYAMAINFO.BO)
PRISMMEDI.BO vs SHYAMAINFO.BO Comparison August 2026
Prism Medico and Pharmacy Limited (BSE: PRISMMEDI.BO) plays a significant role within the Financial Services sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 179.8M. In comparison, SHYAMAINFO.BO has a market cap of 0. Regarding current trading prices, PRISMMEDI.BO is priced at ₹29.65 on the BSE, while SHYAMAINFO.BO trades at ₹7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of 94.76, whereas SHYAMAINFO.BO's P/E ratio is N/A. In terms of profitability, PRISMMEDI.BO's ROE is -0.03%, compared to SHYAMAINFO.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to SHYAMAINFO.BO. This indicates higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check SHYAMAINFO.BO's competition here